Details der Publikation - Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

Abstract Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in Behçet’s disease (BD). This study was aimed at reporting the largest experience with anti-IL-1 agents in BD patients. We evaluated 30 BD patients receiving treatment with anti-IL-1 agents. The primary aims of the study were to evaluate the efficacy of anakinra (ANA) and canakinumab (CAN) in a cohort of BD. The secondary aims were to evaluate the overall safety profile of the treatments, explore the timing of response to therapy and any adjustment of dosage and frequency of drugs studied, and investigate predictive factors of response to therapy. The frequency of first line therapy was 90 % with ANA and 10 % with CAN. The overall number of subjects in complete remission after 12 months of therapy with anti-IL-1 drugs was 13: 6 maintained the initial therapy regimen, 1 maintained the same initial anti-IL-1 drug with further therapeutic adjustments, and the remaining 6 shifted from ANA to CAN. Among them, 3 used CAN for at least 12 months without therapeutic adjustments, 1 had therapeutic adjustments, and 3 had an overall history of a 12-month complete remission. Adverse events (AEs) were reported in 15 % patients who received ANA, represented in all cases by local cutaneous reactions, while no AE were observed in patients who received CAN; we did not observe any serious AEs (SAEs) during the follow-up period. Our data have confirmed that the use of anti-IL-1β drugs is efficacious and safe with an overall acceptable retention on treatment..

Medienart:	E-Artikel

Erscheinungsjahr:	2015
Erschienen:	2015

Enthalten in:	Zur Gesamtaufnahme - volume:35
Enthalten in:	Clinical rheumatology - 35(2015), 5 vom: 10. Juli, Seite 1281-1286

Sprache:	Englisch

Beteiligte Personen:	Emmi, Giacomo [VerfasserIn] Talarico, Rosaria [VerfasserIn] Lopalco, Giuseppe [VerfasserIn] Cimaz, Rolando [VerfasserIn] Cantini, Fabrizio [VerfasserIn] Viapiana, Ombretta [VerfasserIn] Olivieri, Ignazio [VerfasserIn] Goldoni, Matteo [VerfasserIn] Vitale, Antonio [VerfasserIn] Silvestri, Elena [VerfasserIn] Prisco, Domenico [VerfasserIn] Lapadula, Giovanni [VerfasserIn] Galeazzi, Mauro [VerfasserIn] Iannone, Florenzo [VerfasserIn] Cantarini, Luca [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.00$jMedizin: Allgemeines 44.83$jRheumatologie$jOrthopädie
Themen:	Anakinra Anti-interleukin-1 Behçet’s disease Biologics Canakinumab Therapy

Anmerkungen:	© International League of Associations for Rheumatology (ILAR) 2015

doi:	10.1007/s10067-015-3004-0

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2109239166

Internformat


LEADER	01000naa a22002652 4500
001	OLC2109239166
003	DE-627
005	20230502165820.0
007	cr uuu---uuuuu
008	230502s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10067-015-3004-0 \|2 doi
035			\|a (DE-627)OLC2109239166
035			\|a (DE-He213)s10067-015-3004-0-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
082	0	4	\|a 610 \|q VZ
084			\|a 44.00$jMedizin: Allgemeines \|2 bkl
084			\|a 44.83$jRheumatologie$jOrthopädie \|2 bkl
100	1		\|a Emmi, Giacomo \|e verfasserin \|4 aut
245	1	0	\|a Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © International League of Associations for Rheumatology (ILAR) 2015
520			\|a Abstract Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in Behçet’s disease (BD). This study was aimed at reporting the largest experience with anti-IL-1 agents in BD patients. We evaluated 30 BD patients receiving treatment with anti-IL-1 agents. The primary aims of the study were to evaluate the efficacy of anakinra (ANA) and canakinumab (CAN) in a cohort of BD. The secondary aims were to evaluate the overall safety profile of the treatments, explore the timing of response to therapy and any adjustment of dosage and frequency of drugs studied, and investigate predictive factors of response to therapy. The frequency of first line therapy was 90 % with ANA and 10 % with CAN. The overall number of subjects in complete remission after 12 months of therapy with anti-IL-1 drugs was 13: 6 maintained the initial therapy regimen, 1 maintained the same initial anti-IL-1 drug with further therapeutic adjustments, and the remaining 6 shifted from ANA to CAN. Among them, 3 used CAN for at least 12 months without therapeutic adjustments, 1 had therapeutic adjustments, and 3 had an overall history of a 12-month complete remission. Adverse events (AEs) were reported in 15 % patients who received ANA, represented in all cases by local cutaneous reactions, while no AE were observed in patients who received CAN; we did not observe any serious AEs (SAEs) during the follow-up period. Our data have confirmed that the use of anti-IL-1β drugs is efficacious and safe with an overall acceptable retention on treatment.
650		4	\|a Anakinra
650		4	\|a Anti-interleukin-1
650		4	\|a Behçet’s disease
650		4	\|a Biologics
650		4	\|a Canakinumab
650		4	\|a Therapy
700	1		\|a Talarico, Rosaria \|4 aut
700	1		\|a Lopalco, Giuseppe \|4 aut
700	1		\|a Cimaz, Rolando \|4 aut
700	1		\|a Cantini, Fabrizio \|4 aut
700	1		\|a Viapiana, Ombretta \|4 aut
700	1		\|a Olivieri, Ignazio \|4 aut
700	1		\|a Goldoni, Matteo \|4 aut
700	1		\|a Vitale, Antonio \|4 aut
700	1		\|a Silvestri, Elena \|4 aut
700	1		\|a Prisco, Domenico \|4 aut
700	1		\|a Lapadula, Giovanni \|4 aut
700	1		\|a Galeazzi, Mauro \|4 aut
700	1		\|a Iannone, Florenzo \|4 aut
700	1		\|a Cantarini, Luca \|4 aut
773	0	8	\|i Enthalten in \|t Clinical rheumatology \|d Springer London, 1982 \|g 35(2015), 5 vom: 10. Juli, Seite 1281-1286 \|h Online-Ressource \|w (DE-627)27159909X \|w (DE-600)1480901-1 \|w (DE-576)088704351 \|x 1434-9949 \|7 nnns
773	1	8	\|g volume:35 \|g year:2015 \|g number:5 \|g day:10 \|g month:07 \|g pages:1281-1286
856	4	0	\|u https://dx.doi.org/10.1007/s10067-015-3004-0 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.00$jMedizin: Allgemeines \|q VZ \|0 106409646 \|0 (DE-625)106409646
936	b	k	\|a 44.83$jRheumatologie$jOrthopädie \|q VZ \|0 106409425 \|0 (DE-625)106409425
951			\|a AR
952			\|d 35 \|j 2015 \|e 5 \|b 10 \|c 07 \|h 1281-1286

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände